Advertisement

Topics

Seattle Genetics, Inc. Company Profile

03:37 EST 19th November 2017 | BioPortfolio

Seattle Genetics is a clinical-stage biotechnology company focused on the development and commercialization of monoclonal antibody-based therapies for the treatment of cancer and autoimmune disease. The company's lead product candidate, brentuximab vedotin (SGN-35), is in a pivotal trial under a Special Protocol Assessment with the U.S. Food and Drug Administration. Brentuximab vedotin is being developed in collaboration with Millennium: The Takeda Oncology Company. In addition, Seattle Genetics has five other clinical-stage programs: lintuzumab (SGN-33), dacetuzumab (SGN-40), SGN-70, SGN-75 and ASG-5ME. Seattle Genetics has collaborations for its ADC technology with multiple biotechnology and pharmaceutical companies, including Bayer, Celldex Therapeutics, Daiichi Sankyo, Genentech, GlaxoSmithKline, MedImmune, a subsidiary of AstraZeneca, Millennium: The Takeda Oncology Company and Progenics, as well as an ADC co-development agreement with Agensys, an affiliate of Astellas. More information can be found at http://www.seattlegenetics.com.


News Articles [667 Associated News Articles listed on BioPortfolio]

Genentech and Seattle Genetics study ADC/PD-L1 combo for breast cancer

Genentech Inc. and Seattle Genetics Inc. entered a trial collaboration in which they will evaluate the combination of Seattle Genetics investigational antibody-drug conjugate SGNLIV1A with Genentech...

BMS Washington state facility purchased by Seattle Genetics

Bristol-Myers Squibb's Monte Villa Parkway Research Center in Bothell, Wash., has been acquired by Seattle Genetics for $43.3 -More- 

Genmab, Seattle Genetics to co-develop tisotumab vedotin for solid tumors

Genmab and Seattle Genetics announced that Seattle Genetics has exercised its option to co-develop tisotumab vedotin.

Seattle Genetics to Host Conference Call and Webcast Discussion of Second Quarter Financial ...

Seattle Genetics, Inc.InvestorsPeggy Pinkston, 425-527-4160ppinkston@seagen.comorMediaBrandi Robinson, 425-527-2910brobinson@seagen.com Read more...

US FDA accepts Seattle Genetics' sBLA for Adcetris in CTCL and grants priority review status

Seattle Genetics has announced that the US Food and Drug Administration (FDA) has accepted for filing a supplemental Biologics License Application (BLA) based on data from the phase 3 ALCANZA

US FDA approve Seattle Genetics' Adcetris for pcALCL and CD30─expressing mycosis fungoides

Seattle Genetics has announced that the US Food and Drug Administration (FDA) has approved Adcetris (brentuximab vedotin) for the treatment of adult patients with primary cutaneous anaplastic large ce...

Seattle Genetics gains first production site through $43m BMS plant buy

Seattle Genetics paid Bristol-Myers Squibb $17.8m for the biomanufacturing site and says it will spend a further $25.5m on equipment and improvements to support antibody production.

Seattle Genetics' Adcetris accepted for FDA review

Seattle Genetics' supplemental biologics license application for Adcetris, or brentuximab vedotin, was accepted for FDA revie -More- 

PubMed Articles [526 Associated PubMed Articles listed on BioPortfolio]

The Clinic Is My Laboratory: Life as a Clinical Geneticist.

Clinical genetics is the application of advances in genetics and medicine to real human families. It involves diagnosis, care, and counseling concerning options available to affected individuals and t...

Introduction to behavioral phenotypes in medical genetics.

Abstracts from the 2017 Conference on Retroviruses and Opportunistic Infections. February 13-16, 2017. Seattle, Washington.

Seattle's Law Enforcement Assisted Diversion (LEAD): Program effects on recidivism outcomes.

Drug users and dealers frequently cycle through the criminal justice system in what is sometimes referred to as a "revolving door." Arrest, incarceration and prosecution have not deterred this recidiv...

25 more years.

This month, to celebrate a quarter century of excellence in genetics, we are highlighting selections from the past work we have published. We will then publish a number of forward-looking Perspectives...

Clinical Trials [320 Associated Clinical Trials listed on BioPortfolio]

Impact of Non-Commercialism Policy in Seattle Schools

This pilot study on the impact of a non-commercialism policy in Seattle schools will assess and evaluate obesity-related health outcomes of a real-life policy decision, recently voted on a...

Genetics Education: Preparing Physicians for the Future

This study examines the best way to teach genetics to family medicine residents. First year family medicine residents at the University of Toronto will be taught basic clinical genetics as...

Impact of Non-Commercialism Policy in Seattle Schools

This is a 3-year pilot study funded by National Institute of Health will assess and evaluate obesity-related health outcomes of a real-life policy decision, recently voted on and adopted b...

Reproducibility of Malaria Challenge in Healthy Volunteers

This is a prospective, single arm, single intervention safety and immunogenicity study in 6 healthy, malaria-naive adults, conducted to demonstrate the successful implementation of the wel...

Experiences of Genetics Patients With Visible Abnormalities Who Facilitate Teaching in Genetics Clinics

This study will describe the experience of patients with visible physical abnormalities in the genetics clinic when they are involved in teaching others about their condition. Information ...

Companies [241 Associated Companies listed on BioPortfolio]

AccessDNA, Inc.

AccessDNA is the leading online consumer resource for genetics. The company combines high-quality content about genetics with access to, and evaluation of, relevant testing, couns...

Ambry Genetics Corporation

Ambry Genetics is a privately held healthcare company with the industry’s most comprehensive suite of genetic testing solutions, benefiting 90% of all U.S. patients covered b...

Interleukin Genetics, Inc.

Interleukin Genetics, Inc. (OTCQB: ILIU) develops and markets a line of genetic tests under the Inherent Health® brand. The products empower individuals to prevent ce...

Seattle Genetics

Seattle Genetics, Inc. is a biotechnology company developing monoclonal antibody-based therapies for the treatment of cancer and autoimmune diseases. Our strategy is focused on advancing our portfolio...

Population Genetics

Harnessing The Power of Populations™ Population Genetics’ approach takes the process of genetic analysis one step further. It enables the elaboration and testing of distinct hypotheses...

More Information about "Seattle Genetics, Inc." on BioPortfolio

We have published hundreds of Seattle Genetics, Inc. news stories on BioPortfolio along with dozens of Seattle Genetics, Inc. Clinical Trials and PubMed Articles about Seattle Genetics, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Seattle Genetics, Inc. Companies in our database. You can also find out about relevant Seattle Genetics, Inc. Drugs and Medications on this site too.

Quick Search
Advertisement
 

Relevant Topics

Biotechnology
Antibodies Antisense Assays Biochips Bioinformatics Biological Therapy Biomarkers Biomaterials Bioscience Cell Culture Cloning Cytokine Diagnostics Dna Extraction Dna Sequencing Dna Transform...

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...

Autoimmune Disorders
Autoimmune disorders are conditions that occurs when the immune system mistakenly attacks and destroys healthy body tissue. There are more than 80 different types of autoimmune disorders. Normally the immune system's white blood cells help protect ...


Corporate Database Quicklinks



Searches Linking to this Company Record